JP2024517355A - 血管内皮炎の治療において使用するための中間分子量ヘパリン - Google Patents
血管内皮炎の治療において使用するための中間分子量ヘパリン Download PDFInfo
- Publication number
- JP2024517355A JP2024517355A JP2023570373A JP2023570373A JP2024517355A JP 2024517355 A JP2024517355 A JP 2024517355A JP 2023570373 A JP2023570373 A JP 2023570373A JP 2023570373 A JP2023570373 A JP 2023570373A JP 2024517355 A JP2024517355 A JP 2024517355A
- Authority
- JP
- Japan
- Prior art keywords
- molecular weight
- weight heparin
- intermediate molecular
- vwf
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2106972.9 | 2021-05-14 | ||
| GBGB2106972.9A GB202106972D0 (en) | 2021-05-14 | 2021-05-14 | Medium molecular weight heparin |
| PCT/EP2022/063222 WO2022238587A1 (en) | 2021-05-14 | 2022-05-16 | Medium molecular weight heparin for use in the treatment of endotheliopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517355A true JP2024517355A (ja) | 2024-04-19 |
| JP2024517355A5 JP2024517355A5 (https=) | 2025-05-26 |
Family
ID=76550734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570373A Pending JP2024517355A (ja) | 2021-05-14 | 2022-05-16 | 血管内皮炎の治療において使用するための中間分子量ヘパリン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240245718A1 (https=) |
| EP (1) | EP4337225A1 (https=) |
| JP (1) | JP2024517355A (https=) |
| CN (1) | CN117915923A (https=) |
| AU (1) | AU2022273186A1 (https=) |
| CA (1) | CA3219993A1 (https=) |
| GB (1) | GB202106972D0 (https=) |
| WO (1) | WO2022238587A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106117A1 (en) * | 2023-11-17 | 2025-05-22 | Glycos Biomedical Ltd. | Medium molecular weight heparin |
| GB202407360D0 (en) * | 2024-05-23 | 2024-07-10 | Glycos Biomedical Ltd | Functionalised medium molecular weight heparin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20014665A3 (cs) * | 1999-06-30 | 2002-05-15 | Hamilton Civic Hospitals Research Development, Inc | Prostředek s obsahem heparinu se střední molekulovou hmotností |
| EP3348270A1 (en) * | 2017-01-11 | 2018-07-18 | Fytagoras B.V. | Medium molecular weight heparin |
| JP2021155334A (ja) * | 2018-05-01 | 2021-10-07 | 学校法人近畿大学 | 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物 |
| WO2022016098A1 (en) * | 2020-07-17 | 2022-01-20 | Xostem Ip, Inc. | Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes |
-
2021
- 2021-05-14 GB GBGB2106972.9A patent/GB202106972D0/en not_active Ceased
-
2022
- 2022-05-16 WO PCT/EP2022/063222 patent/WO2022238587A1/en not_active Ceased
- 2022-05-16 CN CN202280045684.XA patent/CN117915923A/zh active Pending
- 2022-05-16 EP EP22729556.5A patent/EP4337225A1/en active Pending
- 2022-05-16 AU AU2022273186A patent/AU2022273186A1/en active Pending
- 2022-05-16 CA CA3219993A patent/CA3219993A1/en active Pending
- 2022-05-16 JP JP2023570373A patent/JP2024517355A/ja active Pending
- 2022-05-16 US US18/290,533 patent/US20240245718A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB202106972D0 (en) | 2021-06-30 |
| EP4337225A1 (en) | 2024-03-20 |
| US20240245718A1 (en) | 2024-07-25 |
| WO2022238587A1 (en) | 2022-11-17 |
| CN117915923A (zh) | 2024-04-19 |
| AU2022273186A1 (en) | 2024-01-04 |
| CA3219993A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Best et al. | The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial | |
| US5939429A (en) | Cardiovascular uses of cannabinoid compounds | |
| KR20140053881A (ko) | 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체 | |
| JP2024517355A (ja) | 血管内皮炎の治療において使用するための中間分子量ヘパリン | |
| JP2012514014A (ja) | 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物 | |
| JP2001506603A (ja) | 抗―Ｘａ活性を有する化合物及び血小板凝集拮抗剤化合物を含有する製薬組成物 | |
| Lowe | Pathophysiology of critical leg ischaemia | |
| Sinzinger et al. | Pleiotropic effects of regular lipoprotein-apheresis | |
| Rikken et al. | Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction–A post hoc analysis of the cel-02 phase IIa study | |
| Ogawa et al. | Increased levels of platelet-derived microparticles in pulmonary hypertension | |
| Jankowska-Sanetra et al. | Incidence and course of acute coronary syndrome cases after the first wave of the COVID-19 pandemic | |
| WO2024105271A1 (en) | Preparation of medium molecular weight heparin | |
| Lunetta et al. | Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease | |
| Gupta et al. | Heparin-induced thrombocytopenia | |
| Tsipis et al. | Novel oral anticoagulants in peripheral arterial and coronary artery disease | |
| HK40109661A (zh) | 用於治疗内皮病的中分子量肝素 | |
| Dixon et al. | Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery | |
| Ades et al. | Factor XI inhibitors: potential role in end-stage kidney disease | |
| JP2025537781A (ja) | 中間分子量ヘパリンの調製 | |
| Bendel et al. | Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation | |
| WO2025106117A1 (en) | Medium molecular weight heparin | |
| WO2025245445A1 (en) | Functionalised medium molecular weight heparin | |
| Armstrong et al. | Pharmacology of hemostasis and thrombosis | |
| Kon et al. | Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition | |
| Shi et al. | Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250515 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250515 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260428 |